OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
7
Results
Show all
Save search
Copy query
Show results for
Unknown
(7)
Publication Date
Release Date
2021
(4)
2024
(1)
2018
(1)
2010
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
Not available
S-EPMC5993168
|
biostudies-literature
Cite
Preliminary model assessing the cost-effectiveness of preoperative chlorhexidine mouthwash at reducing postoperative pneumonia among abdominal surgery patients in South Africa.
Not available
S-EPMC8360544
|
biostudies-literature
Cite
Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study.
Not available
S-EPMC2851387
|
biostudies-literature
Cite
Early sedation with dexmedetomidine in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE III randomised controlled trial.
Not available
S-EPMC7939103
|
biostudies-literature
Cite
Socializing One Health: an innovative strategy to investigate social and behavioral risks of emerging viral threats.
Not available
S-EPMC8122533
|
biostudies-literature
Cite
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic.
Not available
S-EPMC10364875
|
biostudies-literature
Cite
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
Not available
S-EPMC12056793
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets